
Commit Biologics raises $60M seed round to advance novel immune therapy for cancer and autoimmune diseases
Commit Biologics secured $60 million in seed funding led by Ackermans & van Haaren with participation from AbbVie Ventures, M Ventures, and others. The funds will support clinical development of COM002, a first-in-class immune engager targeting cance...





